Navigation Links
Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
Date:1/13/2010

18-year track record of success building leading life science and bio-based chemical companies, including cellulosic ethanol pioneer Verenium Corporation

MARLBOROUGH, Mass., Jan. 13 /PRNewswire-USNewswire/ --  Qteros, Inc., a leading developer of second-generation technology solutions for the biofuels industry based on its unique Q Microbe(TM) platform, announced today that John McCarthy has joined the company as President and Chief Executive Officer  to accelerate the company's technology and commercial initiatives in the worldwide cellulosic ethanol marketplace.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100113/DC37180LOGO-b)

(Photo: http://www.newscom.com/cgi-bin/prnh/20100113/DC37180-a)

Mr. McCarthy's 18-year experience includes managing the transformational growth of numerous leading life science and bio-based chemical companies into high-value commercial entities. He has raised over $1 billion of capital in the private and public markets, and developed and executed numerous complex and large-scale strategic corporate partnerships.  

Mr. McCarthy joins Qteros from Microbia, Inc., where he served as Chief Business Officer of this developer of unique bio-based specialty chemicals for large-scale industrial applications. Prior to Microbia, Mr. McCarthy was Executive Vice President for publicly-traded Verenium Corporation, a pioneering leader in the development and commercialization of cellulosic ethanol and specialty enzymes.  At Verenium, McCarthy served as the chief architect of the company's growth from a small privately-held business into a publicly-traded leader in the industry through the successful merger and integration of Celunol and Diversa and the subsequent creation and execution of the industry's precedent-setting strategic corporate partnership with BP plc.

"We are thrilled to have John join us at this important stage of Qteros' development to lead and accelerate our technical, commercial and organizational growth plans," stated Steve Goldby, Qteros board member and Partner at Venrock Associates. "John's experience building pioneering companies in the biofuels industry such as Verenium, together with his proven track record of developing and managing complex strategic corporate partnerships, make him uniquely qualified to lead and position Qteros for significant growth."

"I am very pleased and excited to be joining Qteros at this critical stage of its development, and look forward to accelerating our technical and commercial plans as we focus on making our Q-Microbe™ platform a cellulosic ethanol industry standard," stated McCarthy.

"The broad alternative energy industry represents one of the most important and high-growth opportunities for this generation," McCarthy added. "I look forward to positioning Qteros and its partners as a leading technology solution to support the multi-billion gallon per year U.S. mandate and worldwide requirement for cellulosic ethanol production."

Mr. McCarthy's prior experience includes senior executive positions at Xanthus Pharmaceuticals, Synta Pharmaceuticals, Exact Sciences, Concentra Managed Care, and Morgan Stanley. Mr. McCarthy graduated with high honors from Lehigh University and received his MBA from the Harvard Business School.

About Qteros, Inc.

Qteros is a venture capital-backed company committed to delivering innovative process technologies for clean transportation fuels that reduce greenhouse gas emissions at a price competitive with gasoline. The company is currently in the process of scaling up a unique microbial solution for the highly efficient and cost effective conversion of non-food plants and waste into clean transportation fuel. The company's patented Q Microbe™ system converts a wide array of cellulosic biomass directly into ethanol in a single step, consolidating enzymatic hydrolysis and fermentation, largely eliminating costly enzymes and associated pretreatments, and greatly simplifying the entire production process. Qteros' scientists and business team are dedicated to producing liquid fuels to achieve a sustainable solution to the world's growing energy needs. Qteros has been funded by some of the leading investors in the alternative energy industry, including among others, Venrock Associates, Battery Ventures, BP Technology Ventures, Soros Fund Management LLC and Valero Energy Corporation.  For more information, visit www.Qteros.com.

SOURCE Qteros, Inc.

RELATED LINKS
http://www.qteros.com/

'/>"/>

SOURCE Qteros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
2. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
5. NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
6. NexGen Biofuels Ltd. Announces Trading on OTC Bulletin Board
7. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
8. Performance Plants Establishes U.S. Biofuels Facility
9. NexGen Biofuels Ltd. Announces Plans to Replace its CFO With Local CFO
10. New Generation Biofuels Set to Join Russell Microcap Index
11. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... Franz Inc. , an early innovator ... announced the availability of AllegroGraph 6, the leading Semantic Graph Database with certification ... Program (CCPT). AllegroGraph is the first Semantic Graph Database to be certified ...
(Date:2/8/2016)... England , February 8, 2016 ... Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) ... to CE Mark its Chlamydia trachomatis (CT) test to be ... of the IVD Directive (98/79/EC), the CT test is now ... --> --> The launch of the io® ...
(Date:2/5/2016)... Feb. 5, 2016  In the pharmaceutical industry the ... host of launch activities including the identification and engagement ... activity is especially high in the oncology therapeutic area ... Practices and the Role of Medical Affairs in Oncology ... on oncology therapies find better ways to utilize medical ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf ... today announced an interactive FDA compliance training course, Writing Effective ... Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones and ...
Breaking Biology Technology:
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
Breaking Biology News(10 mins):